{
    "xml": "<topic id=\"PHP5568\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/irinotecan-hydrochloride\" basename=\"irinotecan-hydrochloride\" title=\"IRINOTECAN HYDROCHLORIDE\">\n<title>IRINOTECAN HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1006\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/irinotecan\">Irinotecan</xref>\n</p>\n<data name=\"vtmid\">108783005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_215732037\" title=\"Topoisomerase I inhibitors\">Topoisomerase I inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP34702\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Irinotecan inhibits topoisomerase I, an enzyme involved in DNA replication.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34688\" outputclass=\"indicationsAndDose\" rev=\"1.15\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Metastatic colorectal cancer in combination with fluorouracil and folinic acid or as monotherapy when treatment containing fluorouracil has failed</p>\n<p outputclass=\"therapeuticIndication\">Treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer after failure of chemotherapy that has included irinotecan (in combination with cetuximab)</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of metastatic carcinoma of the colon or rectum (in combination with fluorouracil, folinic acid and bevacizumab)</p>\n<p outputclass=\"therapeuticIndication\">First-line treatment of metastatic colorectal carcinoma (in combination with capecitabine with or without bevacizumab)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34720\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Bowel obstruction</ph>; <ph outputclass=\"contraindication\">chronic inflammatory bowel disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34732\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Raised plasma-bilirubin concentration</ph>; <ph outputclass=\"caution\">risk factors for cardiac disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34685\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (irinotecan).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74387\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Interstitial pulmonary disease</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acute cholinergic syndrome (with early diarrhoea) and delayed diarrhoea (consult product literature)</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">anorexia</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal effects (delayed diarrhoea requiring prompt treatment may follow irinotecan treatment)</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">myelosuppression (dose limiting)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34726\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;manufacturer advises effective contraception during and for up to 1 month after treatment in women and up to 3 months after treatment in men.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34677\" outputclass=\"pregnancy\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic and toxic in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34739\" outputclass=\"breastFeeding\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34693\" outputclass=\"hepaticImpairment\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if plasma-bilirubin concentration greater than 3 times upper limit of normal range.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Monitor closely for neutropenia if plasma-bilirubin concentration 1.5&#8211;3 times upper limit of normal range (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34669\" outputclass=\"renalImpairment\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74371\" outputclass=\"monitoringRequirements\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor respiratory function.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP74354\" outputclass=\"nationalFunding\" rev=\"1.18\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA93</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005)</p>\r\n<p>A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer.</p>\r\n<p>Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA93\">www.nice.org.uk/TA93</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5568-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/irinotecan-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75506\" title=\"Solution for infusion\" namespace=\"/drugs/irinotecan-hydrochloride/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1006\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/irinotecan\" title=\"Irinotecan\" count=\"1\" rel=\"link\">Irinotecan</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75506\" namespace=\"/drugs/irinotecan-hydrochloride/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5568",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/irinotecan-hydrochloride",
    "basename": "irinotecan-hydrochloride",
    "title": "IRINOTECAN HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_1006",
            "label": "Irinotecan"
        }
    ],
    "vtmid": "108783005",
    "drugClassification": [
        "Topoisomerase I inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Irinotecan inhibits topoisomerase I, an enzyme involved in DNA replication.",
                "html": "<p>Irinotecan inhibits topoisomerase I, an enzyme involved in DNA replication.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Metastatic colorectal cancer in combination with fluorouracil and folinic acid or as monotherapy when treatment containing fluorouracil has failed",
                        "html": "Metastatic colorectal cancer in combination with fluorouracil and folinic acid or as monotherapy when treatment containing fluorouracil has failed"
                    },
                    {
                        "textContent": "Treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer after failure of chemotherapy that has included irinotecan (in combination with cetuximab)",
                        "html": "Treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer after failure of chemotherapy that has included irinotecan (in combination with cetuximab)"
                    },
                    {
                        "textContent": "First-line treatment of metastatic carcinoma of the colon or rectum (in combination with fluorouracil, folinic acid and bevacizumab)",
                        "html": "First-line treatment of metastatic carcinoma of the colon or rectum (in combination with fluorouracil, folinic acid and bevacizumab)"
                    },
                    {
                        "textContent": "First-line treatment of metastatic colorectal carcinoma (in combination with capecitabine with or without bevacizumab)",
                        "html": "First-line treatment of metastatic colorectal carcinoma (in combination with capecitabine with or without bevacizumab)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Bowel obstruction",
                "html": "Bowel obstruction"
            },
            {
                "type": "contraindications",
                "textContent": "chronic inflammatory bowel disease",
                "html": "chronic inflammatory bowel disease"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Raised plasma-bilirubin concentration",
                "html": "Raised plasma-bilirubin concentration"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for cardiac disease",
                "html": "risk factors for cardiac disease"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (irinotecan).",
                "html": "<p>Appendix 1 (irinotecan).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Interstitial pulmonary disease",
                        "html": "Interstitial pulmonary disease",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Acute cholinergic syndrome (with early diarrhoea) and delayed diarrhoea (consult product literature)",
                        "html": "Acute cholinergic syndrome (with early diarrhoea) and delayed diarrhoea (consult product literature)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anorexia",
                        "html": "anorexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal effects (delayed diarrhoea requiring prompt treatment may follow irinotecan treatment)",
                        "html": "gastro-intestinal effects (delayed diarrhoea requiring prompt treatment may follow irinotecan treatment)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression (dose limiting)",
                        "html": "myelosuppression (dose limiting)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;manufacturer advises effective contraception during and for up to 1 month after treatment in women and up to 3 months after treatment in men.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;manufacturer advises effective contraception during and for up to 1 month after treatment in women and up to 3 months after treatment in men.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic and toxic in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic and toxic in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if plasma-bilirubin concentration greater than 3 times upper limit of normal range.",
                "html": "<p>Avoid if plasma-bilirubin concentration greater than 3 times upper limit of normal range.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor closely for neutropenia if plasma-bilirubin concentration 1.5&#8211;3 times upper limit of normal range (consult product literature).",
                "html": "<p>Monitor closely for neutropenia if plasma-bilirubin concentration 1.5&#8211;3 times upper limit of normal range (consult product literature).</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor respiratory function.",
                "html": "<p>Monitor respiratory function.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA93",
                        "label": "www.nice.org.uk/TA93"
                    }
                ],
                "fundingIdentifier": "NICE TA93",
                "textContent": "Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005) A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer. Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently.\n\nwww.nice.org.uk/TA93",
                "html": "<p outputclass=\"title\">Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005)</p> <p>A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer.</p> <p>Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA93\">www.nice.org.uk/TA93</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75506",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1006",
                "label": "Irinotecan",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75506",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}